GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » EBITDA Margin %

Meribank Biotech Co (ROCO:4724) EBITDA Margin % : 8.59% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Meribank Biotech Co's EBITDA for the six months ended in Dec. 2024 was NT$20.3 Mil. Meribank Biotech Co's Revenue for the six months ended in Dec. 2024 was NT$236.1 Mil. Therefore, Meribank Biotech Co's EBITDA margin for the quarter that ended in Dec. 2024 was 8.59%.


Meribank Biotech Co EBITDA Margin % Historical Data

The historical data trend for Meribank Biotech Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co EBITDA Margin % Chart

Meribank Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial -15.41 -42.07 -38.91 -39.50 -1.86

Meribank Biotech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.88 -42.19 -37.39 -20.81 8.59

Competitive Comparison of Meribank Biotech Co's EBITDA Margin %

For the Biotechnology subindustry, Meribank Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meribank Biotech Co's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Meribank Biotech Co's EBITDA Margin % falls into.


;
;

Meribank Biotech Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Meribank Biotech Co's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-6.827/366.43
=-1.86 %

Meribank Biotech Co's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=20.291/236.102
=8.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Meribank Biotech Co  (ROCO:4724) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Meribank Biotech Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Meribank Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co Headlines

No Headlines